Can immune cells plus a checkpoint drug outsmart lymphoma?

NCT ID NCT03843294

Ongoing Disease control Sponsor: Catherine Bollard Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This early-stage trial is testing whether a combination of tumor-specific immune cells (TAA-T) and the drug nivolumab can safely help people with lymphoma that has returned or not responded to treatment. Participants receive two infusions of TAA-T cells along with nivolumab, which is designed to boost the immune system's ability to fight cancer. The study aims to assess safety and see if the combination can shrink tumors or prevent relapse after a stem cell transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tumor-associated antigen-specific T cells (TAA-T) combined with nivolumab
What this could lead to: If safe and effective, this combination could offer a new treatment option for patients with lymphoma that has not responded to standard therapies.
What could go wrong: This is an early-phase trial with a small number of participants, so the benefits are uncertain. There is a risk of side effects from the T cells or nivolumab, and the treatment may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma Hodgkins lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA HODGKIN LYMPHOMA

Contacts and locations

Locations

Utah University School of Medicine/Huntsman Cancer Institute

Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.